As thousands of 2019 Corona virus disease (Covid-19) clinical trials are continuously getting added to various registries these days, good practices on data sharing and transparency have become one of the prime topics of discussion than ever before. Although trial registration is considered a crucial step, there is a lack of integration between registration and published literature. Trial outcomes are a matter of public interest, but sponsor compliances are not adequate with the recommended guidelines. Although the global recognition of data transparency increases day by day, there is still a long journey to travel. It is high time that scholarly publishing stakeholders should put in a collaborative effort to check author compliance. In this article, we aimed to comprehend and discuss the imperative roles of various scholarly publishing stakeholders in improving clinical trial transparency during this pandemic situation and highlight the changing paradigm towards the pressing need for reporting clinical trial data more effectively.

中文翻译：

---

临床试验透明度法规：对各种学术出版利益相关者的影响

如今，随着成千上万的 2019 年冠状病毒病 (Covid-19) 临床试验不断被添加到各种登记处，数据共享和透明度的良好做法已成为比以往任何时候都讨论的主要话题之一。尽管试验注册被认为是一个关键步骤，但注册与已发表文献之间缺乏整合。试验结果是公共利益问题，但赞助商的合规性不足以符合推荐的指南。尽管全球对数据透明度的认可度与日俱增，但仍任重道远。现在是学术出版利益相关者应该共同努力检查作者合规性的时候了。在本文中，